Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
23
HYPD Quote, Financials, Valuation and Earnings
Last price:
$3.96
Seasonality move
:
31.9%
Day range:
$3.50 - $4.09
52-week range:
$0.85 - $17.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
102.90x
P/B ratio:
0.45x
Volume:
408.6K
Avg. volume:
416.5K
1-year change:
-49.26%
Market cap:
$32.1M
Revenue:
$57.3K
EPS (TTM):
-$21.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
-- | -- | -- | -- | -- |
|
DARE
Daré Bioscience, Inc.
|
-- | -$0.40 | 2911.81% | -13.48% | $10.75 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
OMER
Omeros Corp.
|
-- | -$0.48 | -- | -0.15% | $28.00 |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$145.8K | -$0.44 | -6.58% | -18.27% | $14.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
$3.97 | -- | $32.1M | -- | $0.00 | 0% | 102.90x |
|
DARE
Daré Bioscience, Inc.
|
$1.79 | $10.75 | $25.6M | 95.38x | $0.00 | 0% | 361.34x |
|
GOVX
GeoVax Labs, Inc.
|
$0.38 | $9.63 | $11.4M | -- | $0.00 | 0% | 1.66x |
|
OMER
Omeros Corp.
|
$11.03 | $28.00 | $782M | -- | $0.00 | 0% | -- |
|
SPRO
Spero Therapeutics, Inc.
|
$2.28 | $4.00 | $128.5M | 10.75x | $0.00 | 0% | 4.32x |
|
VTGN
Vistagen Therapeutics, Inc.
|
$4.28 | $14.50 | $169M | -- | $0.00 | 0% | 150.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 19.509 | 13.53% | 2.04x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | 0.176 | 27.91% | 1.09x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.075 | -- | 2.75x |
|
OMER
Omeros Corp.
|
254.22% | -1.203 | 126.5% | 0.76x |
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 12.710 | 3.17% | 3.63x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 0.724 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
Hyperion DeFi, Inc. vs. Competitors
-
Which has Higher Returns HYPD or DARE?
Daré Bioscience, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -154904.35%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About HYPD or DARE?
Hyperion DeFi, Inc. has a consensus price target of --, signalling downside risk potential of -49.62%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 500.56%. Given that Daré Bioscience, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.0 0 0 DAREDaré Bioscience, Inc.3 0 0 -
Is HYPD or DARE More Risky?
Hyperion DeFi, Inc. has a beta of 2.805, which suggesting that the stock is 180.539% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.917%.
-
Which is a Better Dividend Stock HYPD or DARE?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or DARE?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 102.90x versus 361.34x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M DAREDaré Bioscience, Inc.361.34x 95.38x $2.3K -$3.6M
-
Which has Higher Returns HYPD or GOVX?
GeoVax Labs, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -630.04%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About HYPD or GOVX?
Hyperion DeFi, Inc. has a consensus price target of --, signalling downside risk potential of -49.62%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 2409.12%. Given that GeoVax Labs, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.0 0 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is HYPD or GOVX More Risky?
Hyperion DeFi, Inc. has a beta of 2.805, which suggesting that the stock is 180.539% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.
-
Which is a Better Dividend Stock HYPD or GOVX?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or GOVX?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Hyperion DeFi, Inc.'s net income of $6.6M is higher than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 102.90x versus 1.66x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M GOVXGeoVax Labs, Inc.1.66x -- -- -$6.3M
-
Which has Higher Returns HYPD or OMER?
Omeros Corp. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of --. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About HYPD or OMER?
Hyperion DeFi, Inc. has a consensus price target of --, signalling downside risk potential of -49.62%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 153.85%. Given that Omeros Corp. has higher upside potential than Hyperion DeFi, Inc., analysts believe Omeros Corp. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.0 0 0 OMEROmeros Corp.2 2 0 -
Is HYPD or OMER More Risky?
Hyperion DeFi, Inc. has a beta of 2.805, which suggesting that the stock is 180.539% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.
-
Which is a Better Dividend Stock HYPD or OMER?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or OMER?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Omeros Corp. quarterly revenues of --. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 102.90x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns HYPD or SPRO?
Spero Therapeutics, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -242.19%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M -
What do Analysts Say About HYPD or SPRO?
Hyperion DeFi, Inc. has a consensus price target of --, signalling downside risk potential of -49.62%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 75.44%. Given that Spero Therapeutics, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.0 0 0 SPROSpero Therapeutics, Inc.0 2 0 -
Is HYPD or SPRO More Risky?
Hyperion DeFi, Inc. has a beta of 2.805, which suggesting that the stock is 180.539% more volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.482, suggesting its more volatile than the S&P 500 by 48.19%.
-
Which is a Better Dividend Stock HYPD or SPRO?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or SPRO?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 102.90x versus 4.32x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M
-
Which has Higher Returns HYPD or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -7525.97%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About HYPD or VTGN?
Hyperion DeFi, Inc. has a consensus price target of --, signalling downside risk potential of -49.62%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 238.79%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.0 0 0 VTGNVistagen Therapeutics, Inc.4 0 0 -
Is HYPD or VTGN More Risky?
Hyperion DeFi, Inc. has a beta of 2.805, which suggesting that the stock is 180.539% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.
-
Which is a Better Dividend Stock HYPD or VTGN?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or VTGN?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 102.90x versus 150.22x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M VTGNVistagen Therapeutics, Inc.150.22x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
